Merck signs DNA licensing deal with Vertex

28-01-2019

Merck signs DNA licensing deal with Vertex

Artur / iStockphoto.com

German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases (DNA-PK) inhibitors.


Merck Group, Vertex, CRISPR/Cas9, DNA-PK, Belén Garijo, patent licensing, gene editing, oncology

LSIPR